Preventive effects of Ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients.
Development of dialysis therapy over the last decade caused considerable increase in the number of patients receiving haemodialyses as kidney substitution therapy. However, a wider use resulted in greater number of A-V fistula complications. Uraemia patients were reported to develop plasmatic and platelet haemostasis disorders which provoke dialysis fistula thrombosis. The aim of the paper was to answer how Ticlopidine affected decrease in the number of late thrombosis complications in freshly created A-V fistula. The study included 60 patients, 30 of whom were given Ticlopidine (125 mg twice every 24h). The other 30 patients constituted the control group and did not received the drug. The follow-up lasted 27 months. It was concluded that preventive administration of Ticlopidine significantly reduces the extent of late thrombosis complications.
Janicki
Krzysztof
K
1st Department of Surgery and Transplantology, Medical University of Lublin, Lublin, Poland.
Bojarska-Szmygin
Anna
A
Pietura
Radosław
R
Janicka
Lucyna
L
D000328:Adult; D000368:Aged; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D006435:Renal Dialysis; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013988:Ticlopidine / Q000008:administration & dosage*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine